Tomohiro Kawamoto

机构：Axcelead Drug Discovery Partners Inc. (Japan), Takeda (Japan) · ORCID：0000-0002-2985-5948

发表论文 110 篇 · 总被引 2871 次 · h-index 30

代表论文

• CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor (2017 · Nature Communications · 被引 140)
• Discovery of 3-Benzyl-1-( trans -4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors (2018 · Journal of Medicinal Chemistry · 被引 65)
• Identification of the first highly selective inhibitor of human lactate dehydrogenase B (2021 · Scientific Reports · 被引 62)
• A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer’s disease and tauopathy in mice (2021 · Scientific Reports · 被引 57)
• CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens (2017 · Scientific Reports · 被引 49)
• Discovery of selective ATP-competitive eIF4A3 inhibitors (2017 · Bioorganic & Medicinal Chemistry · 被引 49)